Lifearc

LifeArc funds translational research project grants, with a particular focus on rare diseases in children. Specific programmes have included joint calls for translational research on rare childhood diseases, repurposing therapies for epidermolysis bullosa (EB), and accelerator grants supporting pre-clinical testing, clinical trials and the development of devices and diagnostics. The work is typically carried out at UK hospitals, universities and research institutes, though some calls are open to applicants worldwide. Funding is available for research that moves discoveries towards patient benefit, including activities such as testing existing therapies for new uses. Most grant-making is UK-wide, reflecting the charity’s close ties to the UK biomedical research community. Emphasis is placed on areas of significant unmet need where commercial funders may be less active.

LifeArc accepts applications from UK-based hospitals, universities and research institutes. Academic and non-profit research institutions are eligible, as are hospitals. Commercial companies cannot lead projects, but small and medium-sized enterprises and larger bio/pharma companies may take part as co-investigators without requesting funding. The charity’s programmes often target benefits for children with rare diseases and people living with conditions such as epidermolysis bullosa. Applicants should be able to demonstrate a clear translational focus, taking research from early discovery towards patient-facing outcomes. Some calls are restricted to UK organisations, while others are open internationally, so it is worth checking the specific programme guidance for the relevant call.

LifeArc does not typically support fundamental discovery research, new drug discovery, or standalone model or biomarker development. In its epidermolysis bullosa call, the charity also excluded gene and cell therapies targeting the underlying defect, industry R&D costs, and generic wound-healing or oncology drugs lacking a robust rationale for use in EB. Commercial companies cannot lead applications. Funding is focused on translational research rather than basic science, and projects are expected to have a clear route towards patient benefit.

LifeArc awards multi-year grants for specific translational research projects, often in partnership with other charities and research organisations. The charity welcomes unsolicited applications, though many programmes are run as themed joint calls. Funding supports activities such as pre-clinical testing, clinical trials and the development of devices and diagnostics, with an emphasis on collaboration and co-funding. LifeArc acts as a connector in the research ecosystem, bringing together academic institutions, hospitals and industry partners to advance work that might otherwise struggle to find support.